Netvax

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Alfa toksoid Clostridium-perfringens-type-A

Available from:

Intervet International BV

ATC code:

QI01AB08

INN (International Name):

adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens

Therapeutic group:

Piščanec

Therapeutic area:

Imunologija za aves

Therapeutic indications:

Za aktivno imunizacijo piščancev, ki zagotavljajo pasivno imunizacijo proti nekrotičnemu enteritisu na njihove potomce, so med obdobjem polaganja. Za zmanjšanje smrtnosti ter incidenco in resnost poškodb, ki jih povzroča nekrotični enteritis, ki ga povzroča Clostridium-perfringens tipa A,. Učinkovitost je pokazala izziv piščancev približno tri tedne po izvalitvi. Začetek pasivnega prenosa imunosti: 6 tednov po zaključku postopka cepljenja. Trajanje pasivnega prenosa imunosti: 51 teden po zaključku postopka cepljenja.

Product summary:

Revision: 2

Authorization status:

Umaknjeno

Authorization date:

2009-04-16

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
15
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
16
NAVODILO ZA UPORABO
Netvax, emulzija za injiciranje za piščance
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Intervet International B.V.
Wim de Körverstraat 35
5831AN Boxmeer
Nizozemska
Izdelovalec, odgovoren za sprostitev serije:
S-P Veterinary Ltd
Breakspear Road South
Harefield
Uxbridge
Middlesex, UB9 6LS
Združeno kraljestvo
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Netvax, emulzija za injiciranje za piščance
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN
En odmerek (0,5ml) vsebuje:
Zdravilna učinkovina:
_Clostridium perfringens_ tipa A, toksoid alfa
ne manj kot 6,8 i.e.*
Dodatek
lahko mineralno olje
0,31 ml
Pomožne snovi
tiomersal
0,035-0,05 mg
* mednarodne enote na ml kunčjega seruma, določeno s preizkusom
zaviranja hemolize
4.
INDIKACIJA(E)
Za aktivno imunizacijo piščancev proti nekrotičnemu enteritisu v
času nesnosti in prenos pasivne
zaščite na njihove potomce.
Za zmanjšanje pogina ter pojavnosti in resnosti okvar pri
nekrotičnem enteritisu, ki jih povzroča
bakterija _Clostridium perfringens_ tipa A. Učinkovitost je dokazana
z izzivnim preizkusom pri
piščancih približno tri tedne po izvalitvi.
Prenos pasivne imunosti: 6 tednov po končanem postopku cepljenja.
Trajanje prenesene pasivne imunosti: 51 tednov po končanem postopku
cepljenja.
Zdravilo nima veā dovoljenja za promet
17
5.
KONTRAINDIKACIJE
Niso znane.
6.
NEŽELENI UČINKI
Po intramuskularnem cepljenju niso bile opažene nikakršne sistemske
spremembe. Cepljenje lahko
povzroči zmerno oteklino tkiva na prsih, ki v 30 dneh mine. Po drugem
cepljenju lahko takšna oteklina
traja najmanj 35 dni. Oteklina je bila zelo pogosta.
Po dajanju dvojnega odmerka se lahko nekoliko povečajo lokalne
reakcije (glejte poglavje 4.6).
Če opazite kakršne ko
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-06-2014
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-06-2014
Public Assessment Report Public Assessment Report Bulgarian 11-06-2014
Patient Information leaflet Patient Information leaflet Spanish 11-06-2014
Public Assessment Report Public Assessment Report Spanish 11-06-2014
Patient Information leaflet Patient Information leaflet Czech 11-06-2014
Public Assessment Report Public Assessment Report Czech 11-06-2014
Patient Information leaflet Patient Information leaflet Danish 11-06-2014
Public Assessment Report Public Assessment Report Danish 11-06-2014
Patient Information leaflet Patient Information leaflet German 11-06-2014
Public Assessment Report Public Assessment Report German 11-06-2014
Patient Information leaflet Patient Information leaflet Estonian 11-06-2014
Public Assessment Report Public Assessment Report Estonian 11-06-2014
Patient Information leaflet Patient Information leaflet Greek 11-06-2014
Public Assessment Report Public Assessment Report Greek 11-06-2014
Patient Information leaflet Patient Information leaflet English 11-06-2014
Public Assessment Report Public Assessment Report English 11-06-2014
Patient Information leaflet Patient Information leaflet French 11-06-2014
Public Assessment Report Public Assessment Report French 11-06-2014
Patient Information leaflet Patient Information leaflet Italian 11-06-2014
Public Assessment Report Public Assessment Report Italian 11-06-2014
Patient Information leaflet Patient Information leaflet Latvian 11-06-2014
Public Assessment Report Public Assessment Report Latvian 11-06-2014
Patient Information leaflet Patient Information leaflet Lithuanian 11-06-2014
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-06-2014
Public Assessment Report Public Assessment Report Lithuanian 11-06-2014
Patient Information leaflet Patient Information leaflet Hungarian 11-06-2014
Summary of Product characteristics Summary of Product characteristics Hungarian 11-06-2014
Public Assessment Report Public Assessment Report Hungarian 11-06-2014
Patient Information leaflet Patient Information leaflet Maltese 11-06-2014
Public Assessment Report Public Assessment Report Maltese 11-06-2014
Patient Information leaflet Patient Information leaflet Dutch 11-06-2014
Public Assessment Report Public Assessment Report Dutch 11-06-2014
Patient Information leaflet Patient Information leaflet Polish 11-06-2014
Public Assessment Report Public Assessment Report Polish 11-06-2014
Patient Information leaflet Patient Information leaflet Portuguese 11-06-2014
Summary of Product characteristics Summary of Product characteristics Portuguese 11-06-2014
Public Assessment Report Public Assessment Report Portuguese 11-06-2014
Patient Information leaflet Patient Information leaflet Romanian 11-06-2014
Public Assessment Report Public Assessment Report Romanian 11-06-2014
Patient Information leaflet Patient Information leaflet Slovak 11-06-2014
Public Assessment Report Public Assessment Report Slovak 11-06-2014
Patient Information leaflet Patient Information leaflet Finnish 11-06-2014
Public Assessment Report Public Assessment Report Finnish 11-06-2014
Patient Information leaflet Patient Information leaflet Swedish 11-06-2014
Public Assessment Report Public Assessment Report Swedish 11-06-2014
Patient Information leaflet Patient Information leaflet Norwegian 11-06-2014
Summary of Product characteristics Summary of Product characteristics Norwegian 11-06-2014
Patient Information leaflet Patient Information leaflet Icelandic 11-06-2014
Summary of Product characteristics Summary of Product characteristics Icelandic 11-06-2014

View documents history